Product News


Labs in Europe that perform standard COVID-19 testing can now test for SARS-CoV-2, influenza A, and influenza B simultaneously during the flu season, using the Reliance SARS-CoV-2/FluA/FluB™ RT-PCR Kit (IVD).

The solution includes chromogenic medium and a selective supplement that can detect these bacteria without the need for a confirmation step, delivering results in less than 24 hours.
The StarBright Violet 570, StarBright Violet 670, and StarBright Violet 710 Dyes offer improved brightness and resolution.
The kit improves assay efficiency by eliminating irrelevant RNA fragments from an RNA-Seq library.
The real-time reverse-transcription PCR (RT-PCR) assay kit can detect nucleic acid in SARS-CoV-2, the virus associated with COVID-19 disease.
The assays detect current SARS-CoV-2 variants of concern including P.1, B.1.351, and B.1.1.7 by distinguishing specific mutations using reverse transcription PCR (RT-PCR)
Bio-Rad has announced the launch of two ddPCR Assays for Droplet Digital PCR (ddPCR) platforms that support the development and manufacture of safe and effective cell and gene therapies.
The qualitative multiplex immunoassay panel provides precise, specific, and sensitive detection of IgG antibodies against four SARS-CoV-2 antigens.
Bio-Rad announced that its Reliance SARS-CoV-2/FluA/FluB RT-PCR and Reliance SARS-CoV-2 RT-PCR Assay Kits were granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA).
Studies address how ddPCR technology is helping to alleviate an array of pain points in cell and gene therapy QC in the areas of product safety testing, QC scale-up, and contamination detection.